MGMT and central nervous system cancer: It emphasizes the molecular classification for gliomas, such as isocitrate dehydrogenase (IDH) gene mutations, epidermal growth factor receptor (EGFR) status, methyl-guanine methyltransferase (MGMT) promoter methylation status, and chromosome 1p/19q codeletion.